Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 217 clinical trials
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)

The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB

absolute neutrophil count
platelet count
l aspartate
delamanid
potassium
  • 325 views
  • 16 May, 2022
  • 25 locations
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB

and adolescents (0 months to less than [<] 18 years of age) diagnosed with confirmed or probable pulmonary multidrug resistant tuberculosis (MDR-TB), in combination With a Background Regimen (BR

chest x-ray
tmc207
extensively drug-resistant tuberculosis
pulmonary tuberculosis
bedaquiline
  • 140 views
  • 30 Apr, 2022
  • 7 locations
Impact of SFV of Proximal Colon on ADR

. Inflammatory bowel disease or intestinal tuberculosis. Familial polyp syndrome. Recovery of polyp specimens failed, and no histopathological data. Patients with coagulation dysfunction. Patients 18

  • 0 views
  • 23 Jul, 2021
  • 1 location
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (AFFINITY)

The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to a prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy by assessing clinical response compared with guselkumab monotherapy.

spondylitis
psoriasis
infliximab
arthritis mutilans
adalimumab
  • 5 views
  • 02 May, 2022
  • 27 locations
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (LYRA)

The purpose of this study is to evaluate the dose-response of bermekimab efficacy in participants with moderate to severe Hidradenitis Suppurativa (HS).

adalimumab
abscess
  • 124 views
  • 04 May, 2022
  • 38 locations
Assessing PA-824 for Tuberculosis (the APT Trial)

Assess the mycobactericidal activity of PA-824 (given at 200 mg daily) when added to first-line tuberculosis (TB) treatment (isoniazid, pyrazinamide, and a rifamycin antibiotic) over 12 weeks of

rifamycin
smear
pyrazinamide
ethambutol
acid-fast bacilli
  • 200 views
  • 21 Mar, 2022
  • 1 location
Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis

The purpose of this study is to assess the safety, early bactericidal activity (EBA) and pharmacokinetics of TBA-7371 in adult participants with rifampicin-sensitive tuberculosis and select dose

x-rays
sputum smear
oophorectomy
mycobacterium tuberculosis
smear
  • 3 views
  • 09 Apr, 2022
  • 4 locations
Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis

Rationale Treatment in tuberculosis (TB) is focused on eradication of the bacterial infection, however, after treatment approximately half of patients are left

  • 0 views
  • 19 Apr, 2022
  • 1 location
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion

This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in HIV-infected and HIV-uninfected adults measured by PET/CT.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)

Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIb trial to evaluate efficacy of RUTI® vaccine in DS- (Drug-Sensitive) and MDR-TB (Multidrug-resistant) patients favourably responding to standard MDR-TB treatment. Time point of vaccination starts upon completion of 1 week of standard DS-TB treatment (cohort A), and another cohort of patients will …

  • 0 views
  • 07 Apr, 2022
  • 1 location